From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: ACITRETIN, LEFLUNOMIDE, PENICILLAMINE
ACITRETIN · General benefit
1 INDICATIONS
SORIATANE (acitretin) is indicated for:
• Severe psoriasis (includes erythrodermic and pustular types)
• Other disorders of keratinization
Severe psoriasis is a condition that involves more than 10% of body surface area or is physically,
occupationally or psychologically disabling.
PM: https://pdf.hres.ca/dpd_pm/00080165.PDF; date APR 04, 2025; DIN 02070847; fetched 2026-09-10
Product monograph
APREMILAST · Off-Formulary Interchangeable, not an ODB benefit
Indications
• Plaque Psoriasis
OTEZLA (apremilast) is indicated for the treatment of adult patients with moderate to
severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
PM: https://pdf.hres.ca/dpd_pm/00084256.PDF; date 2026-04-10; DIN 02434318; fetched 2026-09-10
Product monograph
BIMEKIZUMAB · Limited Use, codes 641
Indications
Bimzelx (bimekizumab injection) is indicated for:
• Psoriasis (PsO)
The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for
systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10
Product monograph
• Psoriasis (PsO)
The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for
systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10
Product monograph
ETANERCEPT · Limited Use, codes 512, 513, 514, 563, 591 (3), Limited Use, codes 498, 499, 514, 563, 591 (4)
• treatment of adult patients with chronic moderate to severe plaque psoriasis (PsO) who are
candidates for systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00083562.PDF; date August 31, 2016; DIN 02455323; fetched 2026-09-10
Product monograph
INFLIXIMAB · Limited Use, codes 468, 469, 470, 471, 477, 478, 479 (2), Limited Use, codes 541, 542, 543, 544, 545, 546, 547 (1), Limited Use, codes 715, 716, 718 (2), Limited Use, codes 592, 593, 594, 595, 596, 597, 598 (1)
• treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates
for systemic therapy. For patients with chronic moderate plaque psoriasis, RemdantryTM should
be used after phototherapy has been shown to be ineffective or inappropriate. When assessing
the severity of psoriasis, the health professional should consider the extent of involvement,
location of lesions, response to previous treatments, and impact of disease on the patient’s
PM: https://pdf.hres.ca/dpd_pm/00081840.PDF; date September 2, 2025; DIN 02419475; fetched 2026-09-10
Product monograph
LEFLUNOMIDE · General benefit
ARAVA is indicated in adults for the treatment of active rheumatoid arthritis.
1.1 Pediatrics
The use in patients less than 18 years of age is contraindicated.
1.2 Geriatrics
No dosage adjustment is needed in patients over 65 years of age.
PM: https://pdf.hres.ca/dpd_pm/00083555.PDF; date not captured; DIN 02241888; fetched 2026-09-10
Product monograph
METHOTREXATE · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4)
• Severe disabling psoriasis/psoriatic arthritis
PM: https://pdf.hres.ca/dpd_pm/00078227.PDF; date JAN 08, 2025; DIN 02170698; fetched 2026-09-10
Product monograph
PENICILLAMINE · General benefit
INDICATIONS AND CLINICAL USE
CUPRIMINE (penicillamine capsules, USP) is indicated for:
treatment of Wilson's disease
chronic lead poisoning
cystinuria, and
In patients with severe, active rheumatoid arthritis who have failed to respond to an
adequate trial of conventional therapy.
PM: https://pdf.hres.ca/dpd_pm/00054287.PDF; date not captured; DIN 00016055; fetched 2026-09-10
Product monograph
RISANKIZUMAB · Limited Use, codes 574
Indications
SKYRIZI (risankizumab injection) is indicated for:
• the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for
systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00085642.PDF; date 2026-07-08; DIN 02519283; fetched 2026-09-10
Product monograph
SECUKINUMAB · Limited Use, codes 476
Indications
COSENTYX® (secukinumab injection/secukinumab for injection) is indicated for:
Adult patients
Plaque psoriasis
COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who
are candidates for systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00080972.PDF; date not captured; DIN 02529653; fetched 2026-09-10
Product monograph
Hidradenitis Suppurativa
COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis
suppurativa (acne inversa) who have responded inadequately to conventional systemic hidradenitis
suppurativa therapy (see 14.1.5 Hidradenitis suppurativa).
1.1 Pediatrics
Plaque psoriasis
COSENTYX (secukinumab injection/secukinumab for injection) is indicated for the treatment of
moderate to severe plaque psoriasis in patients 6 year and older who are candidates for systemic
therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00080972.PDF; date not captured; DIN 02529653; fetched 2026-09-10
Product monograph
and 3 more
Coverage source: ON formulary extract 2026-08-26